Physician profile
Heather Brooke Clair
NPI 1669932380
$1,196.57
in general payments reported to CMS, 2019-2025
20 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $28.19 · 2022: $208 · 2023: $496 · 2024: $185 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $167.45 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $165.28 | 2022-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $97.89 | 2022-2025 | Zepbound, Kisunla, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $81.22 | 2022-2024 | |
| Glaxosmithkline, LLC. | $72.36 | 2022-2025 | Shingrix, Arexvy |
| Exact Sciences Corporation | $66.73 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $61.44 | 2022-2023 | Quviviq |
| Corcept Therapeutics | $59.37 | 2023 | Korlym |
| Abbvie INC. | $53.56 | 2023-2025 | Vraylar |
| Merck Sharp & Dohme LLC | $49.69 | 2020-2023 | Vaxneuvance, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.56 | 2023 | Jardiance |
| Vivus LLC | $41.84 | 2023-2024 | Qsymia |
| Pfizer INC. | $35.82 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $35.50 | 2022-2025 | Airsupra |
| Ucb, INC. | $33.97 | 2025 | Bimzelx |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $33.40 | 2025 | Auvelity |
| Daiichi Sankyo INC. | $31.47 | 2022-2023 | Injectafer |
| Medtronic, INC. | $30.78 | 2023-2024 | Closurefast, Minimed 770g |
| Sumitomo Pharma America, INC. | $17.47 | 2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $15.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Clair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.